The STAT News article highlights significant advancements in multiple myeloma therapies presented at the 2024 American Society of Hematology (ASH) conference, featuring contributions from Sylvester Comprehensive Cancer Center expert Dr. C. Ola Landgren, who showed promising data supporting the potential FDA approval of daratumumab for the treatment of high-risk smoldering myeloma.